Definium Therapeutics, Inc. (DFTX)
| Market Cap | 2.24B +423.5% |
| Revenue (ttm) | n/a |
| Net Income | -183.79M |
| EPS | -2.06 |
| Shares Out | 99.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,621,508 |
| Open | 23.26 |
| Previous Close | 23.26 |
| Day's Range | 21.71 - 23.44 |
| 52-Week Range | 6.03 - 26.25 |
| Beta | 2.56 |
| Analysts | Strong Buy |
| Price Target | 38.50 (+71.26%) |
| Earnings Date | May 4, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $38.5, which is an increase of 71.26% from the latest price.
News
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Transcript: Investor Day 2026
DT120 is advancing through multiple phase III trials for GAD, MDD, and PTSD, with three pivotal data readouts expected in 2024. The commercial strategy targets high-need patients and leverages robust ...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying ...
Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Pivotal phase III data for DT120 in MDD and GAD are expected this year, with studies designed for robust efficacy and durability assessment. GAD prevalence is rising, and current treatments are inadeq...
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders ...
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
DT-120, a novel LSD tartrate, is advancing through phase III trials for GAD and MDD, with pivotal data expected this year. The studies are robustly designed for broad patient inclusion and durability ...
Definium Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Definium Therapeutics is advancing DT120, an ODT LSD formulation, in phase III trials for GAD and MDD, showing best-in-class efficacy and durable effects. Commercialization plans target a large unmet ...
Definium Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
DT120, a novel LSD-based therapy, showed rapid, durable efficacy in GAD and MDD, with pivotal phase III studies underway and strong regulatory momentum. Surveys indicate high provider enthusiasm, and ...
Definium Therapeutics Earnings Call Transcript: Q4 2025
Late-stage pipeline advanced with four pivotal phase III studies for DT120 ODT in GAD and MDD, strong financial position with $411.6 million in cash, and commercial readiness for potential launches. T...
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeut...
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeut...
Definium Therapeutics Appoints Roger Adsett to Board of Directors
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. “We are ...
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical LSD in Mental Health Care.
Definium Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The organization is advancing DT120, a novel single-dose psychedelic therapy, through multiple phase III trials for GAD and MDD, with pivotal data expected in 2024. Strong clinical results, robust fun...
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or “Definium") is updating its previous announcement that the Company's Common Shares woul...
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
NEW YORK--(BUSINESS WIRE)--MindMed Announces Rebrand to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026.